GM-503
Acne Vulgaris
Phase 1Active
Key Facts
About Galderma Group
Galderma's mission is to advance dermatology for every skin story, leveraging its position as the sole global, scaled pure-play in the field. Its key achievement is building an integrated, three-pillar business model—Therapeutic Dermatology, Injectable Aesthetics, and Dermatological Skincare—that drives growth across medical and consumer markets. The strategy centers on innovation through a proprietary R&D engine, global commercial execution, and capitalizing on its independence post-2019 Nestlé separation and successful 2024 IPO. This approach has established a leading portfolio with strong brand recognition and a robust pipeline.
View full company profileTherapeutic Areas
Other Acne Vulgaris Drugs
| Drug | Company | Phase |
|---|---|---|
| Pipeline Program | MatriSys Bioscience | Preclinical |
| AKVANO®-based Acne treatment | Lipidor | Pre-clinical/Phase 1 |
| Acne & Impure Skin | Pelpharma Handels | Commercial |
| CB-03-01 (Cortexolone 17α-propionate) | Cosmo Pharmaceuticals | Phase III |
| TWYNEO® (tretinoin/BPO) | Sol-Gel Technologies | Commercial |
| SGT-510 | Sol-Gel Technologies | Phase 2 |
| TWYNEO® | Mayne Pharma Group | Marketed |
| TVB-3567 | Sagimet Biosciences | Phase 1 |